Comparison of two drugs for reducing pain intensity in children with neuropathic pain

Comparison of efficacy of Gabapentin and Pregabalin in reducing pain intensity in children with Guillain Barre syndrome 4-18 years of age: a single blind randomized controlled pilot trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078718

Enrollment

Registered

2024-12-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G610- Guillain-Barre syndrome

Interventions

Intervention1: Gabapentin: 10 mg/kg/day daily orally tablets in three divided doses for seven days Control Intervention1: Pregabalin: 3.5 mg/kg/day daily orally tablets in three divided doses for seve

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of GBS Presence of neuropathic pain with severity measured by visual analogue score of 4 or more

Exclusion criteria

Exclusion criteria: Any major chronic systemic illness Previous documented allergy to either gabapentin or pregabalin

Design outcomes

Primary

Measure	Time frame
Pain intensity in bilateral legs measured by the investigator using the visual analog scale on a scale of 0-10Timepoint: Day 3 and day 7 after starting study medication	—

Secondary

Measure	Time frame
Pain intensity in back measured by the investigator using the visual analog scale on a scale of 0-10Timepoint: Day 3 and day 7 after starting study medication	—

Countries

India

Contacts

Public ContactDr Prateek Kumar Panda

All India Institute of Medical Sciences, Rishikesh

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026